Experimental HIV Drugs
Experimental HIV Drugs
IDWeek 2016: Ibalizumab Monoclonal Antibody Looks Promising for HIV Patients Left Behind
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 28 October 2016 00:00
- Written by Liz Highleyman
Ibalizumab, an experimental antiretroviral agent that works differently than existing HIV drugs, demonstrated promising safety and antiviral activity in a small Phase 3 study of people with highly drug-resistant virus, according to a report at the IDWeek conference this week in New Orleans. If confirmed in larger studies, this could be good news for HIV patients who cannot be successfully treated using available therapies.
AIDS 2016: Long-Acting Injectable Drugs Work Well for HIV Maintenance Therapy
- Details
- Category: Experimental HIV Drugs
- Published on Thursday, 21 July 2016 00:00
- Written by Liz Highleyman
A pair of long-acting injectable antiretrovirals -- cabotegravir and rilpivirine -- administered once every 4 or 8 weeks maintained viral suppression in people who switched regimens with undetectable viral load, according to 48-week results from the LATTE-2 trial presented at the 21st International AIDS Conference (AIDS 2016) this week in Durban. A related qualitative analysis showed that study participants preferred long-acting injectables over pills for several reasons.
FDA Approves Descovy TAF Combination Pill for HIV Treatment, Not Yet for PrEP
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 06 April 2016 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) this week approved Gilead Sciences' Descovy, a new combination pill containing tenofovir alafenamide (TAF), which is easier on the kidneys and bones than the older tenfovir disiproxil fumarate (TDF) version. The new coformulation is similar to Truvada, but it has been approved only for use as a component of HIV treatment, not for pre-exposure prophylaxis or PrEP.
ASM Microbe 2016: PRO 140 Antibody Injections Maintain Viral Suppression Off ART
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 22 June 2016 00:00
- Written by Liz Highleyman
Subcutaneous injections of PRO 140, a monoclonal antibody that blocks HIV entry into cells, was well-tolerated and maintained undetectable viral load for more than a year after stopping antiretroviral therapy (ART) in patients with viral suppression, according to a study presented at the ASM Microbe 2016 meeting this week in Boston.
CROI 2016: Long-Acting MK-8591 Could Be Future Option for HIV Treatment and Prevention
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 06 April 2016 00:00
- Written by Michael Carter
Merck's MK-8591, an investigational antiretroviral agent that maintains drug levels that are able to inhibit HIV up to 6 months after dosing could represent a "paradigm shift" in HIV therapy and prophylaxis, according to research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston.
More Articles...
- CROI 2016: Combination Inhibitor BMS-986197 Demonstrates Good Anti-HIV Activity in Early Study
- FDA Approves Second TAF-Containing Single-Tablet HIV Regimen
- CROI 2016: TAF/FTC Maintains Viral Suppression as Well as TDF with Less Bone and Kidney Toxicity
- CROI 2016: Long-Acting Injectable Cabotegravir + Rilpivirine Works Well as HIV Maintenance Therapy
Web Design and Development by